Company intelligence / Profile preview

Uromedica

Plymouth, Minnesota, United Statesuromedica-inc.com ↗

Ownership: Private
Employees: ~26
Development stage: Other

Overview

ProACT™ Adjustable Continence Therapy for Men has been commercially available since FDA approval in November 2015 with over 8,500 implants worldwide as of late-stage reporting. Clinical trials are ongoing for ACT® Adjustable Continence Therapy for Women under an FDA Investigational Device Exemption to evaluate safety and efficacy. The company’s devices are minimally invasive, adjustable after implantation without further surgery, and have demonstrated excellent results internationally. Over 16,000 patients have received Uromedica implants globally.

Therapeutic areas: Men's HealthUrology
Modalities: DeviceImplantable balloon deviceMinimally invasive therapy
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Uromedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uromedica.

Explore the full profile